前列腺癌生活质量的遗传驱动因素:E3805 CHAARTED试验中基因多态性与患者报告结局的评估
该研究为E3805 CHAARTED试验的事后分析,探讨COMT rs4680单核苷酸多态性与转移性激素敏感性前列腺癌患者接受ADT±多西他赛治疗期间生活质量的相关性。结果显示,在ADT单药治疗组中,rs4680携带者相比野生型在3个月时疼痛更轻、疼痛干扰更少,6个月时总体生活质量更优,而ADT+多西他赛组中未观察到COMT状态与生活质量的关联。
要点
- COMT rs4680多态性与ADT单药治疗患者疼痛减轻和总体生活质量改善相关。
- rs4680携带者在3个月时疼痛严重程度显著低于野生型(0.5 vs 1.25;p=0.04)。
- ADT+多西他赛组中,不同COMT状态的患者生活质量相似。
核心结论
- 携带COMT rs4680 SNP的前列腺癌患者在接受ADT单药治疗后疼痛更轻、总体生活质量更好。
- 这是首个表明遗传特征可能影响前列腺癌治疗耐受性的研究。
研究设计与样本
- E3805 CHAARTED试验的事后分析,纳入790名转移性激素敏感性前列腺癌患者,其中550名有COMT SNP数据。
- 在基线及3、6、9、12个月时使用Fisher精确检验和Wilcoxon秩和检验评估COMT rs4680状态与FACT-P、FACIT-F、BPI评分的关联。
主要发现
- 在整个队列中,rs4680携带者3个月疼痛严重程度低于野生型(0.5 vs 1.25;p=0.04)。
- 在ADT单药组,rs4680携带者6个月总体生活质量更优(128.9 vs 118.5;p=0.04)。
- 在ADT单药组,rs4680携带者3个月无疼痛比例更高(70.4% vs 41.5%;p=0.01),3、6、9个月无疼痛干扰比例更高(分别为76% vs 51.3%,p=0.03;75% vs 48.7%,p=0.02;83.3% vs 52%,p=0.02)。
- ADT单药组中rs4680携带者与野生型的疲劳评分相似。
- ADT+多西他赛组中,不同COMT状态的患者生活质量相似。
临床怎么用
- COMT rs4680状态可能有助于识别接受ADT单药治疗时疼痛和生活质量更差的高风险患者。
- 对于携带野生型COMT的患者,可能需要更密切的疼痛和生活质量监测。
局限性
- 为事后分析,结果需前瞻性验证。
- 仅550/790名患者有COMT SNP数据,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The rs4680 single-nucleotide polymorphism (SNP) of the COMT gene leads to a reduction in dopamine clearance, resulting in better mood and a decrease in symptoms in noncancer populations, but its influence on quality of life (QOL) during cancer treatment is undefined. We hypothesized that in comparison to wildtype (WT) COMT, the rs4680 SNP is associated with better QOL among men with metastatic hormone-sensitive prostate cancer receiving androgen deprivation therapy ± docetaxel (ADT ± D). METHODS: In this post hoc analysis, we tested the association between COMT rs4680 status and Functional Assessment of Cancer Therapy-Prostate (overall QOL), Functional Assessment of Chronic Illness Therapy-Fatigue, and Brief Pain Inventory scores at baseline and at 3, 6, 9, and 12 mo using Fisher's exact test and the Wilcoxon rank-sum test. Blood samples for genotyping were collected before treatment initiation. KEY FINDINGS AND LIMITATIONS: COMT SNP data were available for 550/790 men. Across the overall cohort, 3-mo pain severity was lower for rs4680 versus WT COMT (0.5 vs 1.25; p = 0.04). In the ADT arm, rs4680 versus WT COMT was associated with better overall QOL at 6 mo (128.9 vs 118.5; p = 0.04), less pain at 3 mo (no pain: 70.4% vs 41.5%; p = 0.01), and less pain interference at 3 mo (no interference: 76% vs 51.3%; p = 0.03), 6 mo (75% vs 48.7%; p = 0.02), and 9 mo (83.3% vs 52%; p = 0.02), with similar fatigue scores. Patients in the ADT + D arm had similar QOL regardless of COMT status. CONCLUSIONS AND CLINICAL IMPLICATIONS: Patients with the COMT rs4680 SNP experienced less pain and better global QOL after starting ADT alone. This is the first study to show that inherited genetic traits may influence treatment tolerability in men with prostate cancer.
引用
- Sentana-Lledo D, Chu X, Ryan CJ, et al. Genetic Drivers of Quality of Life in Prostate Cancer: An Evaluation of Genetic Polymorphisms and Patient-reported Outcomes in the E3805 CHAARTED trial. Eur Urol Oncol. 2025. PMID: 40246610. doi:10.1016/j.euo.2025.04.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。